Unknown

Dataset Information

0

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.


ABSTRACT: BACKGROUND:PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-06650833 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. METHODS:Study 1 (NCT02224651) was a 96-day, placebo-substitution, SAD study of once-daily (QD) oral PF-06650833 IR 1 to 6000?mg and MR 30 to 300?mg in fasted and fed states. Study 2 (NCT02485769) was a 14-day, placebo-controlled, MAD study of PF-06650833 IR 25 to 750?mg twice daily, IR 1000?mg four times per day, IR 330?mg three times per day, and MR 300?mg QD. RESULTS:PF-06650833 was generally well tolerated, with no dose-limiting treatment-emergent adverse events (TEAEs) identified in either study. TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. No serious AEs or deaths were reported. A maximum tolerated dose was not established in either study. In the SAD study, food intake delayed absorption of IR 30?mg and increased total exposure by 33%. Delayed absorption was achieved with the MR formulation (Tmax of 1?h versus 8?h for IR 100?mg and MR 100?mg formulations, respectively). Food had no effect on total exposure for MR 30?mg, but reduced half-life 1.8-fold and increased Cmax by 62%. In the MAD study, accumulation ranged from 0.9-fold to 1.4-fold for AUCtau and 0.9-fold to 1.3-fold for Cmax. Less than 1% of the dose was recovered unchanged in urine for all dose groups, with renal clearance ranging from 14 to 23?mL/min for IR

SUBMITTER: Danto SI 

PROVIDER: S-EPMC6896740 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.

Danto Spencer I SI   Shojaee Negin N   Singh Ravi Shankar P RSP   Li Cheryl C   Gilbert Steven A SA   Manukyan Zorayr Z   Kilty Iain I  

Arthritis research & therapy 20191205 1


<h4>Background</h4>PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-06650833 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects.<h4>Methods</h4>Study 1 (NCT02224651) was a 96-day, placebo-substitution, SAD study of once-daily (QD)  ...[more]

Similar Datasets

| S-EPMC7496261 | biostudies-literature